Sameek Roychowdhury,Matthew K. Iyer,Dan R. Robinson,Robert J. Lonigro,Yi-Mi Wu,Xuhong Cao,Shanker Kalyana‐Sundaram,Lee Sam,O. Alejandro Balbin,Michael J. Quist,Terrence R. Barrette,Jessica N. Everett,Javed Siddiqui,Lakshmi P. Kunju,Nora M. Navone,John C. Araujo,Patricia Troncoso,Christopher J. Logothetis,Jeffrey W. Innis,David C. Smith
出处
期刊:Science Translational Medicine [American Association for the Advancement of Science (AAAS)] 日期:2011-11-30卷期号:3 (111)被引量:617
The mutations present in advanced cancers can be identified by integrative high-throughput sequencing to enable biomarker-driven clinical trials and, ultimately, treatment.